Murine Study on Pharmacological Inhibition of HPGDS
Research indicates that PGD2 levels are higher in multiple sclerosis (MS) patients and correlate with the frequency of Th17 cells and disease severity. In mice, increased PGD2 worsened symptoms of experimental autoimmune encephalomyelitis (EAE). Deleting Hpgds in CD4+ T cells offered protection against EAE, while inhibiting HPGDS improved symptoms and reduced Th17 differentiation in both mice and human cells.
- Tags
- #MSResearch
- Most relevant to
- —
Why it matters
Understanding the role of PGD2 in MS could uncover new therapeutic targets, particularly related to Th17 cell modulation.
What this does not prove
The study does not provide human clinical data beyond correlation with PGD2 and Th17 cells, limiting conclusions on effectiveness in humans.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-01
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceTargeting the HPGDS-PGD2 axis to treat Th17 cell-mediated autoimmunity in multiple sclerosis. ↗DOI: 10.1038/s41392-026-02937-5
Supporting passages (9)
publication date2026-10-01
interventionpharmacological inhibition of HPGDS
findingsPGD2 is selectively elevated in patients with MS compared with healthy individuals.
findingsWithin the MS cohort, PGD2 correlates with Th17 cell frequency and disease severity.
findingsConsistent with this association, administration of PGD2 increases the severity of experimental autoimmune encephalomyelitis (EAE) in mice.
findingsCD4+ T cell-specific deletion of Hpgds, the key synthase for PGD2, impairs Th17 cell polarization and protects against EAE, whereas exogenous PGD2 restores both Th17 cell responses and disease susceptibility.
findingsImportantly, pharmacological inhibition of HPGDS alleviates EAE symptoms in mice.
findingsConsistently, HPGDS inhibition suppresses Th17 cell differentiation in both murine and human CD4+ T cells, highlighting its translational potential.
limitationsTitle: Targeting the HPGDS-PGD2 axis to treat Th17 cell-mediated autoimmunity in multiple sclerosis.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.